Diabetic eye disease: The urgent need for early, non-invasive treatments
Drug Discovery World
MAY 15, 2024
Currently in a Phase Ib/IIa study, it is believed to stabilise GAP-junction activity through regulation of connexin-43. million by 2029, according to GlobalData. To be widely adopted, there is an urgent need to develop non-invasive therapies that will improve patient welfare as well as compliance, and preserve vision long-term.
Let's personalize your content